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Aim To review the available literature pertaining to fatali-
ties following vaccine administration and, in particular, cas-
es of vaccine-related fatal anaphylaxis.
Method The MEDLINE database was systematically 
searched up to March 2016 to identify all relevant articles 
pertaining to fatal cases of anaphylaxis following vaccine 
administration.
Results Six papers pertaining to fatal anaphylaxis following 
vaccination were found relevant. Mast cell tryptase and to-
tal IgE concentration was assessed exclusively in one case. 
Laryngeal edema was not detected in any of these cases, 
whereas eosinophil or mast cell infiltration was observed 
in lymphoid organs. In one case, immunohistochemical in-
vestigations using anti-tryptase antibodies allowed pulmo-
nary mast cells and degranulating mast cells with tryptase-
positive material outside to be identified.
Conclusion In any suspected IgE-mediated fatal anaphy-
lactic cases, biochemical investigations should be system-
atically performed for forensic purposes. Splenic tissue 
should be routinely sampled for immunohistochemical 
investigations in all suspected anaphylaxis-related deaths 
and mast cell/eosinophil infiltrations should be systemati-
cally sought out in the spleen, myocardium, and coronary 
artery wall. The hypothesis of fatal anaphylaxis following 
vaccination should be formulated exclusively when cir-
cumstantial data, available medical records, laboratory in-
vestigations, and autopsy or histology findings converge 
in a consistent pattern. The reasonable exclusion of alter-
native causes of death after all postmortem investigations 
is also imperative in order to establish or rule out a cause-
and-effect relationship between vaccine administration 
and any presumptive temporarily-related death.
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Vaccination is considered one of the greatest achieve-
ments of public health, with vaccination programs contrib-
uting to the decline in mortality and morbidity of various 
infectious diseases. The high rate of childhood vaccination 
in most developed countries indicates that it remains a 
widely accepted public measure (1).
Although coverage levels for most childhood vaccines re-
main high, numerous studies have documented that vac-
cine-related confidence has been decreasing among par-
ents over the past several years. Vaccine hesitancy refers to 
concerns regarding vaccine safety and necessity. Nonethe-
less, most vaccine-hesitant parents do proceed with vac-
cinations, albeit often with a delay in some or all vaccines 
that potentially leave their children at risk for vaccine-pre-
ventable diseases. Parents who refuse all recommended 
vaccines are relatively rare (1-5).
Access to vaccine information and misinformation from a 
wide range of sources significantly influences vaccine de-
cision-making. Parents may hear a multitude of messages 
regarding vaccination, some of which conflicting or inac-
curate. This may lead to misperceptions that can influence 
vaccine acceptance. Negative media coverage about vac-
cine safety or vaccine-related illnesses, injuries or death 
may correlate with an increased incidence of vaccine-pre-
ventable diseases (1,5).
Hundreds of millions of vaccinations are administered 
to children and adults in the world. Serious adverse re-
actions, including anaphylaxis, are uncommon. However, 
temporarily associated deaths can occur following im-
munization and these require careful postmortem as-
sessment. It is essential to establish whether the death is 
coincidental or causally related to the administered vac-
cination in order to avoid social concerns that may neg-
atively impact public perception or vaccine acceptance, 
if not the actual decision to adhere to vaccination pro-
grams or not (6).
Even though virtually all vaccines have the potential to 
trigger anaphylaxis, the risk of anaphylaxis after vaccina-
tion is extremely low and varies with different vaccine 
types (7,8).
Forensic pathologists may occasionally encounter cases of 
deaths following vaccinations or possibly causally related 
to vaccination due to the unexplained nature of death and 
the potential relationship to the adverse effects of the ad-
ministered vaccine.
There have been very few cases of vaccine-related fatal 
anaphylaxis described in forensic literature. Of those re-
ported, only a small part had undergone the exhaustive 
postmortem investigations necessary to correctly formu-
late the hypothesis of anaphylaxis-related death following 
vaccine administration. These include total and specific IgE 
assessment, mast cell tryptase determination and histo-
logical/immunohistochemical examination (9).
The aim of this study was to review the available litera-
ture pertaining to fatalities following vaccine administra-
tion and, in particular, cases of vaccine-related fatal ana-
phylaxis. These deaths were considered with respect to 
occurrence, patient characteristics, administered vaccine 
and performed biochemical or histological investigations 
as well as any other useful information identified based on 
clinical history and medical record review.
MATERIAL AND METHODS
The MEDLINE database was systematically searched up to 
March 2016 to identify all relevant articles pertaining to 
fatal cases of anaphylaxis following vaccine administra-
tion. The search strategy used the keywords and/or mesh-
terms “anaphylaxis”, “anaphylactic”, “anaphylactoid”, “shock”, 
“allergy”, “allergic”, “nonallergic”, “non-allergic”, “hypersen-
sitivity”, “immediate”, “reaction(s)”, “adverse reaction(s)”, 
“side effect(s)” “adverse effect(s)”, “fatal”, “fatality”, “fatalities”, 
“lethal”, “death”, “forensic”, “medicolegal”, “medico-legal”, 
“tryptase”, “beta-tryptase”, “β-tryptase”, “mast cell tryptase”, 
“postmortem”, “post-mortem” or “autopsy” combined with 
any combination of the following: “vaccine(s)” (“influenza”, 
“pertussis”, “measles”, “mumps”, “rubella”, “pneumococcus/
pneumococcal”, “meningococcus/meningococcal”, “hae-
mophilus”, “encephalitis”, “tuberculosis”, “hepatitis”, “polio-
virus”, “poliomyelitis”, “polio”, “rabies”, “typhoid”, “cholera”, 
“varicella”, “yellow fever”, “zoster”, “tetanus”, “diphtheria”, 
“toxoid(s)”, “hexavalent”, “trivalent”, “quadrivalent”, “pen-
tavalent”, “monovalent”, “papillomavirus”, “rotavirus”), “vac-
cine components”, “vaccination(s)” and “immunization(s)”. 
The reference lists of the selected articles were then hand-
searched for additional, potentially relevant articles. In or-
der to be considered significant for the aim of our study, 
articles had to report fatal anaphylactic reactions follow-
ing vaccine administration, patient characteristics (age, 
gender, medical record availability) and vaccine details. 
The absence of autopsy/histology findings or postmor-
tem biochemical investigation results was not con-
sidered exclusion criteria. Published review articles 
pertaining to fatal reactions to vaccinations were 
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included when data concerning individual fatal cases 
could be obtained. Two reviewers [CP and CT] checked all 
potentially relevant data in order to select pertinent pa-
pers. Of all the latter, full text papers were retrieved for fur-
ther checking of inclusion and exclusion criteria. Articles 
that did not mention patient characteristics (age, gender, 
medical records) and vaccine type were excluded. Inclu-
sion and exclusion criteria were checked independently 
by two reviewers (CT and MPS).
The initial strategy resulted in 517 articles, of which 18 
were related to death following vaccination based on the 
abstracts and/or full texts. After reading the full texts, 6 pa-
pers pertaining to fatal anaphylaxis following vaccination 
were found relevant (Figure 1).
RESULTS
We collected data on autopsy, histology, toxicology and bio-
chemistry, when available in the selected articles (Table 1)
Mast cell tryptase was assessed exclusively in one case and 
revealed a concentration over the clinical reference val-
ues in the living. Total IgE concentration was measured in 
only one case, though without specific IgE and mast cell 
tryptase. Laryngeal edema was not detected in any of 
these cases whereas eosinophil or mast cell infiltration was 
observed in lymphoid organs including the spleen, liver 
and lungs. In one case, immunohistochemical investiga-
tions using anti-tryptase antibodies allowed pulmonary 
mast cells and degranulating mast cells with tryptase-pos-
itive material outside to be identified.
DISCUSSION
An adverse event following vaccine administration is de-
fined as any untoward medical occurrence following its 
administration and does not necessarily have a causal re-
lationship with its use. Deaths following vaccination, espe-
cially when occurring in the first 48 h following vaccine ad-
ministration, are of particular concern because they may 
raise community and health provider questions regarding 
the safety of the administered vaccine as well as the immu-
nization program in general (15,16).
Four categories of suspected adverse events following 
vaccination have been reported: those induced by the in-
jection process, those relating to a direct action of a vac-
cine component, those reflecting an immune-mediated 
process and those due to other mechanisms (17).
FIgURE 1. Search strategy, study selection, and study inclusion.
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Adverse reactions reflecting an immune-mediated pro-
cess include localized inflammatory responses, systemic 
inflammatory reactions, allergic (anaphylactic) reactions 
and other immune-related reactions. Vaccines are a mix-
ture of compounds. Hence, allergic sensitization may occur 
to any component. Moreover, allergic reactions may follow 
administration of the first vaccine dose (7,15-18).
Vaccines include active immunizing antigens (complete mi-
croorganisms or their fragments, such as capsule polysac-
charides), conjugating agents, preservatives, stabilizers, an-
timicrobial agents, adjuvant and culture media used in the 
preparation of the vaccine as well as the excipient used in 
the manufacturing process and inadvertent contaminants 
introduced during vaccine handling. Almost all vaccine 
components can be considered potential, allergic reaction 
triggers. These may include the natural rubber latex that can 
be contained in the syringe plunger as well as in the tips 
on prefilled syringes and vial stoppers. However, culture-
derived proteins from eggs, gelatin (primarily used in viral 
vaccines to stabilize virus viability) and yeast are of particular 
importance. Other sources of allergic reactions are antibiot-
ics and active immunizing antigens (7,9,15,18-23).
The mechanism involved in vaccine-associated allergies is 
generally considered to be a classical type I immediate hy-
TAbLE 1. Fatal presumptive anaphylactic cases following vaccine administration available in the literature
Authors, year 
of publication 
(ref. No.)
Age, 
gender
Administered vaccine
Post-vaccination interval Autopsy
Histology
Immunohistochemistry biochemistry Toxicology
Ziskind and 
Schattenberg, 
1938 (10)
39 year-old 
female
Typhoid vaccine
Second injection
First symptoms 30 min post 
vaccination
Death occurred shortly post 
vaccination
Petechial 
hemorrhages
of the pleural 
surfaces
Generalized 
congestion
Generalized congestion
Compressed pulmonary alveoli with 
congested capillaries along with dilated 
alveoli and ruptured alveolar walls
Eosinophils in the pulmonary vessels. 
Occasional eosinophils in the hepatic 
vessels
Not 
performed
Not 
performed
Walker, 
1948 (11)
20 year-old 
male
Typhus vaccine
Found dead 26 minutes after 
receiving typhus vaccine
Allergic to eggs
Yellow fever vaccine 
administered previously
No visible local 
reaction at 
vaccination location
Generalized 
congestion
Pulmonary edema
Generalized congestion
Pulmonary edema
Not 
performed
Not 
performed
Werne and 
Garrow, 
1946 (12)
10-month-
old male 
identical 
twins
Second injection of diphtheria 
toxoid and pertussis
Death within hours post vac-
cination
Petechial 
hemorrhages
(several organs, 
including thymus)
Pulmonary edema
Generalized 
congestion
Numerous eosinophils in the lymphatic 
tissues, including the thymus
Slight eosinophilic infiltration in 
bronchial and pulmonary artery wall
Not 
performed
Not 
performed
Curphey, 
1947 (13)
3˝-year-old 
female
Influenza type A and B
First symptoms 4 h post 
vaccination
Death 7 h ˝ post vaccination
Generalized 
congestion
Petechial 
hemorrhages
(several organs, 
including thymus)
Occasional eosinophils in the lungs
No eosinophils in the spleen
Moderate eosinophil infiltration in 
lymph node
Not 
performed
Not 
reported
Pounder, 
1983 (14)
33-year-old 
male
Vaccination against typhoid 
and cholera
First symptoms 1 h post 
vaccination
Death 8 h post vaccination
No visible local 
reaction at 
vaccination location
No laryngeal edema
Right atrial and 
ventricular dilatation
Occasional eosinophils sparsely 
scattered in the liver
Cardiac conduction system  
nremarkable
Total 
IgE 720 IU/mL
Not 
reported
D’Errico et al, 
2008 (9)
3-month-
old female
Hexavalent vaccine
Death 24 h post vaccination
Cardiac conduction 
system removed
Immunohistochemistry using anti-
tryptase antibodies.
Pulmonary mast cells and degranulating 
mast cell with tryptase-positive material 
outside identified.
Cardiac conduction system unremarkable
Mast cell 
tryptase 43.3 μg/L
Negative
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persensitivity reaction involving an IgE-mediated response 
against a particular vaccine component. IgE-mediated re-
actions typically occur within minutes to an hour of ex-
posure to relevant allergens and almost always within 4 
hours of causative trigger contact. Type IV hypersensitivity 
delayed reactions have also been reported, though gen-
erally considered harmless. Type IV hypersensitivity reac-
tions start 48 hours after vaccination and peak between 
48 and 96 hours. They are typically observed with vaccines 
containing thimerosal (a mercury-containing preservative 
used in multidose vials that act as a preservative by inhibit-
ing bacterial contamination), aluminum and antimicrobial 
agents in sensitized children and adults. Type IV reactions 
are becoming less frequent as mercury is being removed 
from modern vaccines. Type III hypersensitivity reactions 
have been described more rarely. These are attributed to 
the formation of circulating immune complexes between 
IgG antibodies and vaccine antigens and may induce a se-
rum sickness-like disease or an exanthematous rash over 
6-12 hours. Lastly, some delayed reactions may not be 
immunologically mediated. For instance, persistent hard 
nodules at the injection site have been attributed to local 
inflammatory reactions caused by irritant adjuvants such 
as aluminum and do not necessarily reflect immunologic 
hypersensitivity to vaccine constituents, though allergy to 
aluminum salts has also been proposed as an underlying 
mechanism (7,17,18,24,25).
Mast cells and basophils are the primary effector cells of clas-
sic type I immediate hypersensitivity reactions in humans. On 
the other hand, clinical and experimental experience has in-
dicated that eosinophils are prominently engaged in allergic 
conditions and are implicated in the pathogenesis of ana-
phylaxis. The accumulation of eosinophils and mast cells in 
the spleen appears to be a hallmark of anaphylaxis, though 
it is still unclear whether splenic eosinophil infiltration is 
the consequence of recruitment through locally released 
chemotactic factors or whether it reflects general eosinophil 
increase in blood and tissue due to an allergic disposition. 
While the role of mast cells in human anaphylaxis is rather 
definite, issues such as the identification of the chemotac-
tic factors that attract eosinophils in the spleen and the ma-
jor signaling mechanism(s) for eosinophil activation remain 
poorly understood. Activated mast cells release numerous 
effector molecules, some of which could act as eosinophil 
chemotactic factors and consequently be responsible for 
eosinophil accumulation in the spleen (26-30).
The association between sudden infant death syn-
drome (SIDS), sudden unexpected death in infancy 
and vaccination has been discussed frequently. Because 
of the close temporal association between the first im-
munizations and the main peak of the SIDS incidence, it 
has been speculated that vaccinations may cause SIDS or 
sudden unexpected deaths in infancy. Nevertheless, sev-
eral case-control studies have suggested that the apparent 
association between SIDS/sudden unexpected deaths in 
infancy and vaccinations occurs no more frequently than 
simply by chance or that immunizations may even be pro-
tective against SIDS. These results notwithstanding, the is-
sue arises anew from time to time (16,25,31,32).
In 2003 a German study gave rise to suspicion of a possible 
association between hexavalent vaccine administration 
and sudden unexpected death in infancy. The signal was 
based on the observation of three deaths occurring be-
tween November 2000 and June 2003 in toddlers in their 
second year of life within 48 hours following administra-
tion of the fourth vaccine dose. In what became a heat-
edly discussed and criticized letter, another German team 
described six cases of sudden infant death shortly after 
hexavalent vaccination. In March 2011, Japan’s Health 
Ministry ordered doctors to stop immunizing infants with 
hexavalent vaccines subsequent to the sudden death of 
five babies within a short period of time after administra-
tion (33-39).
It has been emphasized that the definition itself of sud-
den infant death or sudden unexpected death in infancy 
following (hexavalent) vaccination is rather questionable. 
First, exhaustive postmortem examinations in presump-
tive vaccination-related death cases are not systematical-
ly performed. In addition, if examinations are performed, 
they may not include in-depth studies of the autonomic 
nervous system, vital centers of the brainstem or cardiac 
conduction system on serial sections. Morphological ab-
normalities in the brainstem and cardiac conduction sys-
tem (such as arcuate nucleus hypoplasia in the brainstem 
as well as persistent fetal dispersion and resorptive de-
generation in the cardiac conduction system) have been 
proposed in infants dying suddenly and unexpectedly as 
possible morphological substrates for sudden reflexogen-
ic deaths, thus highlighting the importance of extensive 
postmortem investigations in all deaths occurring in infan-
cy and perinatal age shortly after immunization (25,34,40).
As indicated above, vaccines are a mixture of compounds 
and almost all vaccine components can be considered as 
potential triggers to an allergic reaction. Anaphylaxis fol-
lowing vaccination is considered very rare with a docu-
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mented risk in immunization information provided to the 
public of 1-2 cases per million vaccine dose. However, this 
becomes less clear when one considers the published lit-
erature on reported rates of anaphylaxis following vaccina-
tion. Indeed, this varies widely from 0.65 to 120 per million 
vaccines. The significant variation in the reported rate of 
anaphylaxis may be accounted for by a myriad of factors. 
Most importantly of these is case ascertainment and de-
nominator data accuracy (ie, the number of vaccine doses 
administered). Case ascertainment will vary according to 
surveillance method (spontaneous reporting or active sur-
veillance) and used case definition. Factors inherent to the 
target population being vaccinated as well as those inher-
ent to the vaccine composition may also likely contribute 
to the variable rates of anaphylaxis (8,9,15,22-24,41).
The onus anaphylaxis detection as an adverse event fol-
lowing immunization falls into national, post-market sur-
veillance systems, all of which rely on passive cases report-
ing. The reporting system of the Medicines and Healthcare 
Products Regulatory Agency in the UK received 130 reports 
of anaphylaxis associated with immunization in the six 
years from 1997 to 2003, suggesting a rate of 1 per million 
vaccine doses. Likewise, the US Vaccine Adverse Event Re-
porting System (VAERS) recorded 452 reports of reactions 
in over 1.9 billion doses of vaccines administrated country-
wide over a 10-year period. This yields an estimated inci-
dence of 0.2 cases for million vaccine doses. All post-mar-
keting surveillance systems rely on passive case reporting 
and are thus prone to underreporting. These incidences 
are also of overall reaction rates and do not reflect inci-
dences following individual vaccines (8,9,15,19,20).
Case descriptions of anaphylactic reactions to almost all 
vaccines exist. The incidence of anaphylactic reactions to 
the yellow fever vaccine reported to VAERS from 1991 to 
1997 was about 1 per 131.000 doses. The reaction often 
occurred after the first vaccine dose, indicating that ingre-
dients other than the immunizing vaccine antigen itself 
may have been the cause of the allergic reaction. Nagao 
et al. (22) demonstrated significantly increased influenza 
vaccine-specific IgE and vaccine-induced basophil activa-
tion in patients with influenza-vaccine induced anaphylax-
is (IVA) who were included in the IVA spike in 2011-2012 
in Japan. Judging by the number of case reports, the inci-
dence of anaphylactic reactions to vaccines was higher 50 
to 60 years ago than it is today. One reason for this may be 
that diagnostic criteria are more stringent nowadays than 
in the past. Another explanation can be that many of the 
reactions were caused by vaccine impurities. Indeed, im-
proved purification processes have reduced the amount 
of allergenic substances in vaccines. Nevertheless, it can 
be said that severe systemic allergic reactions to vaccines 
were rare even 50 years ago (7-9,18,21-24,30,41,42).
Anaphylaxis-related deaths can present a series of unique 
challenges to forensic pathologists for several reasons. First, 
most forensic cases have incomplete, unreliable or absent 
medical records when bodies are admitted to the mortu-
ary. Additionally, macroscopic and microscopic findings 
may be unspecific or absent. Furthermore, factors consis-
tent with the hypothesis of fatal anaphylaxis include an 
immediately preceding challenge with an allergen known 
to cause reactions, clinical features consistent with or sug-
gesting anaphylaxis, a previous history of reactions to simi-
lar or cross-reactive allergens, specific IgE antibodies to the 
allergen suspected of causing the reaction as well as mea-
surable products of mast cell activation (26,43-45).
In the clinical setting, the diagnosis of anaphylaxis is based 
on consistent symptoms following exposure to potential 
triggering agents and may be further confirmed by in-
creased levels of histamine and mast cell tryptase in plas-
ma or serum. Unfortunately, practical consequences re-
lated to sampling times arise from the differing kinetics of 
histamine and mast cell tryptase appearance and elimina-
tion from blood. Indeed, samples for histamine determina-
tion should be obtained within 15 minutes of anaphylaxis 
onset, which might only be possible in a small proportion 
of cases and precluded in most of them. Conversely, sam-
ples for mast cell tryptase measurement can be obtained 
up to several hours after the reaction begins (26,44,46-49).
Based on the above, histamine determination is of no val-
ue for diagnostic purposes in the forensic setting whereas 
mast cell tryptase is. Indeed, mast cell tryptase levels can 
be assessed in postmortem serum even days after death 
and significantly increased postmortem serum tryptase 
levels have been reported repeatedly in cases of fatal ana-
phylaxis (26,44-47,50,51).
Although elevated postmortem serum tryptase concen-
trations may support the existence of mast cell activation, 
failure to document its elevation does not refute the di-
agnosis of anaphylaxis. Indeed, some cases of clinically 
diagnosed anaphylaxis to orally-ingested food allergens 
failed to show elevated tryptase levels, though abundant 
amounts of IgE against the ingested allergen could be 
detected. Moreover, beyond cases of fatal anaphylaxis, 
increased levels of postmortem serum tryptase have 
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been observed in subjects with causes of death unrelat-
ed to anaphylaxis. This leads to the conclusion that post-
mortem, straightforward diagnoses of anaphylaxis cannot 
be exclusively based on mast cell tryptase determination 
alone (26,44,45,51-58).
Total and specific IgE antibodies appear to be relatively 
stable in postmortem serum samples and their measure-
ments have proven useful for diagnostic purposes. How-
ever, total IgE determination in postmortem serum can 
only provide information pertaining to atopic disposition 
in individual cases. This means that increased levels do not 
prove that death was preceded by an IgE-mediated allergic 
reaction. In addition, similar to mast cell tryptase, increased 
total IgE levels have been observed frequently in situations 
unrelated to anaphylaxis, including diseases characterized 
by immune deficiencies or significant inflammatory com-
ponents (26,44,45,59,60).
It has been proposed that combining results from mast 
cell tryptase determination in postmortem serum with a 
more specific assay for allergen sensitivity (such as aller-
gen-specific postmortem serum IgE assays, if the identity 
of the allergen causing anaphylaxis is known or suspect-
ed) might support the hypothesis of IgE-mediated fatal 
anaphylaxis. Nevertheless, high levels of allergen-specif-
ic IgE exclusively indicate the degree of specific allergen 
sensitization in individual cases and do not prove death 
preceded by anaphylaxis. Hence, increased postmortem 
serum total and specific IgE levels cannot prove fatal aller-
gic anaphylaxis (45,58,60-62).
Activated mast cell and eosinophil accumulation in the 
red pulp of the spleen has been demonstrated by several 
authors in anaphylaxis-related deaths using histochemical 
methods and specific immunohistochemical staining with 
monoclonal antibodies (44,54,63-66).
Today, a general consensus exists among researchers in 
recommending splenic tissue be systematically sampled 
for immunohistochemical investigations in all suspected 
anaphylaxis-related deaths. This is suggested in consider-
ing eosinophil and mast cell accumulation in splenic red 
pulp, along with increased postmortem serum tryptase 
levels, as the most reliable combination of microscopic 
findings and biochemical results to diagnose fatal anaphy-
laxis (44,65).
In addition, systematic histological examination of the 
myocardium and coronary arteries has been recom-
mended by some authors. They suggest traditional and 
specific staining for mast cell identification in order to 
identify adventitial eosinophils and mast cells potentially 
involved in sudden death due to coronary artery spasm 
(67-72).
Very few cases of presumptive fatal anaphylaxis follow-
ing immunization (including vaccine details, autopsy and 
histology findings as well as toxicology and biochemistry 
results when these analyses were performed) have been 
reported in the literature (9-14,73). The most exhaustively 
described case is the one by D’Errico et al. (9) in a 3-month-
old baby who was administered hexavalent immuniza-
tion in 2008. These authors performed not only biochemi-
cal analyses, which allowed an increased level of mast cell 
tryptase (43.3 μg/L) to be measured, but also immunohis-
tochemical investigations using anti-tryptase antibodies, 
which allowed pulmonary mast cells and degranulating 
mast cells with tryptase-positive material outside to be 
identified. Moreover, these authors actually removed the 
cardiac conduction system during autopsy to carry out 
its histological examination. Examination of the system 
proved unremarkable.
The other reported cases, though interesting, lack either 
biochemical analysis or immunohistochemistry. Toxicolo-
gy was only occasionally performed. Hence, the diagnosis 
of vaccination-related fatal anaphylaxis, though sugges-
tive, remains (in our opinion) a mere hypothesis.
An analogous consideration may be applied to the case 
series reported by Zinka et al (35). These authors observed 
a slight eosinophil infiltration in various areas: in the liver 
in four out of six cases, in the lung in two out of six cases, 
in the spleen in just one case and at the cutaneous injec-
tion site in one case. Mast cell tryptase was measured in 
three out of six cases and levels were increased in two out 
of three. IgE levels were normal and specific IgE were as-
sessed exclusively against tetanus toxoid and latex, both 
with negative results.
While the forensic literature on this topic is extremely 
scarce in comparison to other “allergic” or “anaphylactic” fa-
talities (which could lead to the conclusion that fatal ana-
phylaxis following vaccination is indeed an extremely rare 
occurrence, that these cases are only exceptionally inves-
tigated in the medico-legal setting or that they are rare-
ly described in the literature as case reports), a very high 
numbers of papers exist in the clinical setting pertaining to 
vaccination-related deaths and other serious adverse vac-
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cination-related events reported to various national, post-
market surveillance systems. What is surprising “forensi-
cally” speaking, is that almost all these papers document 
a certain number of cases of vaccination-related deaths, 
though autopsy findings and data from death certificates 
are only available in a fraction of them (6,74-79).
If, on one hand, it is true that all post-marketing surveil-
lance systems rely on passive case reporting and are prone 
to underreporting, on the other hand it is true that the 
number of more or less presumptive vaccination-related 
death cases (including presumptive fatal anaphylaxis cas-
es following immunization) that had properly undergone 
in-depth forensic investigations is uncertain. In-depth re-
fers to investigations characterized by histology, immu-
nohistochemistry, biochemistry, toxicology and microbi-
ology as well as microscopic examination of the cardiac 
conduction system and neuropathology with examina-
tion of the autonomic nervous system and vital centers of 
the brainstem in children. The question then arises, from 
a forensic point of view, about how many of these pre-
sumptive vaccination-related death cases or fatal anaphy-
laxis cases following immunization are actually caused by 
the administered vaccine.
Some years ago, the Brighton Collaboration Anaphylaxis 
Working Group developed case definition and guidelines 
for data collection, analysis and presentation for anaphy-
laxis as an adverse event following immunization. This very 
important paper stipulates that, because of uncertainties 
regarding the specificity of mast cell tryptase in the diagno-
sis of anaphylaxis and the absence of vaccine-specific data, 
mast cell tryptase measurement should be performed in 
suspected anaphylaxis cases, though this analysis should 
be considered exclusively as a minor diagnostic criterion. 
Where the presence of antigen specific serum-IgE does not 
necessarily predict clinical allergic manifestations, the ab-
sence of specific IgE does not rule out anaphylaxis. Hence, 
though specific IgE may have a useful role in causality as-
sessment, it is not appropriate in case ascertainment. Lastly, 
the Group emphasizes that since anaphylaxis does not pro-
duce pathognomonic postmortem features, the proposed 
case definition of anaphylaxis should not take autopsy find-
ings into account. On the basis of the conclusions of the 
Group, data from histology and immunohistochemistry are 
not considered in the case definition (80).
In conclusion, from a forensic point of view, all cases of 
sudden unexpected death in both adults and children re-
quire as many postmortem investigations as possible to be 
performed in order to rule out third party involvement and 
ascertain the cause of death as precisely as possible.
Regarding fatalities following drug administration, the 
role of forensic investigations is to determine whether the 
deaths are coincidental or causally related to the admin-
istered drug, irrespective of whether the drug is an anti-
biotic, contrast medium or vaccine. Death causally linked 
to drug administration but above all to obligatory vaccina-
tion may indeed give rise to social concerns, which must 
be avoided as far as possible, in the absence of reliable sci-
entific evidence.
In suspected IgE-mediated fatal anaphylaxis, including fatal 
anaphylaxis potentially following vaccination, biochemical 
investigations should be systematically performed. How-
ever, it is worth emphasizing that increased postmortem 
serum levels of mast cell tryptase, total IgE and specific IgE 
do not prove (individually considered) that death was pre-
ceded by an IgE-mediate event. On the other hand, the ab-
sence of increased postmortem serum levels of mast cell 
tryptase does not allow the hypothesis of fatal anaphylaxis 
(following immunization) to be ruled out.
The accumulation of activated mast cells and eosinophils 
in the red pulp of the spleen has been repeatedly dem-
onstrated in anaphylaxis-related fatalities. Consequently, 
splenic tissue should be routinely sampled for immuno-
histochemical investigations in all suspected anaphylaxis-
related deaths and mast cell/eosinophil infiltrations should 
be systematically sought out in the spleen, myocardium 
and coronary artery wall.
Despite a certain number of uncertainties, eosinophil and 
mast cell accumulation in splenic red pulp, along with in-
creased postmortem serum mast cell tryptase levels, can 
be considered the most reliable combination of micro-
scopic findings and biochemical results in diagnosing fatal 
anaphylaxis in the forensic setting. Within the aforemen-
tioned limits, this same consideration should be applied to 
presumptive fatal anaphylaxis following immunization.
Microscopic evaluation of the cardiac conduction system 
and in-depth neuropathological examination including 
investigation of the autonomic nervous system and vital 
centers of the brainstem should always be performed in 
all cases of sudden unexpected deaths in infancy. This is 
especially important in situations potentially related to 
drug/vaccine administration in order to ascertain the 
role played by the administered medication.
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On the other hand, all cases of sudden unexpected death 
in both adults and children require microbiological, toxico-
logical and biochemical investigations. These are manda-
tory to exclude infection, intoxication and metabolic dis-
turbances as causes of death.
To conclude, we are of the opinion that the hypothesis 
of fatal anaphylaxis following vaccination should be for-
mulated exclusively when circumstantial data, medical 
records when available, and postmortem investigation 
results (mast cell tryptase, total IgE and specific IgE deter-
mination, immunohistochemical research of eosinophil 
and mast cell accumulation in splenic red pulp) converge 
in a consistent pattern. In addition, the reasonable exclu-
sion of alternative causes of death is imperative in order 
to establish or rule out a cause-and-effect relationship be-
tween vaccine administration and any presumptive tem-
porarily-related death.
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